VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed on the Frankfurt Stock Exchange (FSE) under the ticker symbol “7J0”.
This strategic milestone marks Rakovina Therapeutics’ entry into one of the largest equity markets in Europe, providing increased visibility and accessibility to European and global investors. The Frankfurt Stock Exchange listing complements the company’s existing listing on the TSX Venture Exchange (TSX-V: RKV), enabling broader participation in Rakovina Therapeutics’ mission to revolutionize cancer drug discovery.
Global Reach and Accessibility
Rakovina’s listing on the Frankfurt Stock Exchange is expected to enhance its presence in Europe and attract new investors…
